Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 7;19:13. doi: 10.1186/s12951-020-00758-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — pRNA-EGFRapt-siXBP1 NPs silenced XBP1 expression, sensitizes MDA-MB-231 cells to doxorubicin treatment in vitro, reduces cell viability, impairs mammospheres forming ability, but not alters cell apoptosis and cell cycle. a RT-PCR result of XBP1 gene expression in MDA-MB-231 cells after treated with 50 nM NPs. (mean ± s.d., n = 3). ***, p < 0.001. b Western blot analysis of XBP1s and XBP1u expression in MDA-MB-231cells after pRNA-EGFRapt-siXBP1 NPs treatment for 72 h. c Flow cytometry analysis of MDA-MB-231 cells cell cycle alteration after treated by pRNA-EGFRapt-siXBP1 or pRNA-EGFRapt-siScr control, respectively. (mean ± s.d., n = 3). d Cell apoptosis determined by annexin V and 7AAD staining. e Cell viability analysis of MDA-MB-231 cells after treated by NPs or NPs plus dox for 72 h. (mean ± s.d., n = 5–7). ***, p < 0.001. f Quantification of soft agar colony formation in different groups. (mean ± s.d., n = 3). **, p < 0.01. **